TEVA Trumpets Saxenda, Stocks Eke Higher

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) said its U.S. affiliate announced today the FDA approval and U.S. launch of a generic version of Saxenda®1 (liraglutide injection).“With this approval, and by launching a generic for Saxenda® (liraglutide injection), we will provide patients in the U.S. the first ever generic GLP-1 product specifically indicated for weight loss,” said Ernie Richardsen, SVP, Head of U.S. Commercial Generics at Teva. “This is the fifth first-to-market entry of a Teva generic this year and is an important addition to Teva's diverse complex generics portfolio, demonstrating once again our proven ability to sustain a world class Generics Powerhouse.”Saxenda® had annual sales of $165 million as of June 2025.Liraglutide Injection is a glucagon like peptide 1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in:Adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity.Adults with overweight in the presence of at least one weight-related comorbid condition.Liraglutide injection should be used with a reduced calorie diet and increased physical activity.TEVA shares edged higher seven cents to $18.11.